Molecular Partners AG's (NASDAQ: MOLN) collaborating partner Amgen Inc (NASDAQ: AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners following a strategic pipeline review.  MP0310 is a dual-targeted compound targeting both FAP.